Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…Abstract Number: 1210 • 2017 ACR/ARHP Annual Meeting
Non-Responders to Total Joint Replacement Therapy in Osteoarthritis Patients and Novel Metabolic Markers
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, and is the major source of joint pain and disability. The aim of the study…Abstract Number: 1848 • 2017 ACR/ARHP Annual Meeting
NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. The current serological and radiological parameters used to assess disease activity are not…Abstract Number: 2641 • 2017 ACR/ARHP Annual Meeting
Immune Complex-Driven Neutrophil Activation in Systemic Lupus Erythematosus – Novel Biomarkers of Disease Activity and Severity
Background/Purpose: Neutrophil activation is linked to inflammation and autoimmune diseases, including systemic lupus erythematosus (SLE) where nucleic acid-containing immune complexes (ICs) drive inflammation through engagement…Abstract Number: 460 • 2017 ACR/ARHP Annual Meeting
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up
Background/Purpose: The primary aim of this study was to analyse serum levels differences of angiogenic and inflammatory biomarkers between SDAI, CDAI, ACR, DAS28 and sonographic…Abstract Number: 740 • 2017 ACR/ARHP Annual Meeting
Prediction of Fibrosis Progression in Systemic Sclerosis By Collagen Biomarkers
Background/Purpose: Altered extracellular matrix (ECM) remodeling leading to fibrosis is a key pathogenic process in systemic sclerosis (SSc). We previously showed that collagen formation and…Abstract Number: 1268 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JoSLE) is associated with low bone mass for age and fractures, nevertheless risk factors and predictors of bone involvement are…Abstract Number: 1896 • 2017 ACR/ARHP Annual Meeting
IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders
Background/Purpose: Systemic onset Juvenile Idiopathic Arthritis (sJIA) is a disease characterized by systemic inflammation in addition to arthritis and it’s diagnosis currently still depends on…Abstract Number: 2649 • 2017 ACR/ARHP Annual Meeting
Anti-Suprabasin Antibody; A Novel Autoantibody May Contribute to the Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE), an autoimmune disorder characterized by the production of pathogenic autoantibodies and inflammatory mediators, involves multiple organ systems. Neuropsychiatric systemic lupus…Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…Abstract Number: 143 • 2017 Pediatric Rheumatology Symposium
Influence of Age and Sex on Collagen-Induced Arthritis
Background/Purpose: Age and sex differences are found in certain subsets of juvenile idiopathic arthritis (JIA). Collagen Induced Arthritis (CIA) in rodents has utility in assessing…Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 83
- Next Page »